Company overview
Aldevron is a CDMO specializing in plasmid DNA, mRNA, recombinant proteins, and gene editing components for cell and gene therapies from research to commercial scale. They offer GMP manufacturing, process and analytical development, LNP encapsulation, sterile fill/finish, and regulatory support including CMC and IND assistance. With over 25 years of experience, Aldevron ensures scalability and quality for viral and non-viral vectors.
Aldevron is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include aldevron, cdmo, plasmid dna, mrna manufacturing, gene therapy.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Aldevron include Cdmo — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.aldevron.com/
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- aldevron, cdmo, plasmid dna, mrna manufacturing, gene therapy
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What manufacturing capabilities does Aldevron provide for pharma and biotech?
- Aldevron offers GMP manufacturing of plasmid DNA, mRNA, recombinant proteins via E. coli, gene editing enzymes, IVT enzymes, LNP encapsulation, and drug product fill/finish, supporting research through commercial stages.
- What regulatory and development support is available?
- Services include process design, analytical method development and testing, process characterization, CMC experience, IND and regulatory support, and PSQ, with compliant analytics for all quality grades.
- Where are Aldevron's facilities located and what is their track record?
- Aldevron operates facilities including in Madison for enhanced protein capabilities, with over 25 years supporting cell and gene therapy from discovery to commercialization, including proven clinical and commercial manufacturing.
Related editorial coverage
- America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives
- Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance
- $2M Gene Therapy Cures Need a Financing Model
- AI Citation Gap in CDMO Capacity: Pharmaceutical Manufacturing Examples and Insights
- Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
Explore lab tools and QA/QC resources for R&D teams.
